Current evidence on immune-driven depression

Purpose of review This review summarizes recent evidence on immune-driven depression, a subtype of major depressive disorder (MDD) characterized by low-grade inflammation, energy-related symptoms and metabolic disturbances. This subtype is associated with worse outcomes and distinct antidepressant responses. Considering inflammatory features may help clinicians tailor MDD management, particularly by informing lifestyle measures and targeted interventions. The review highlights studies describing features of immune-driven depression, discussing mechanistic pathways, and evaluating mechanism-based interventions. Recent findings Novel mechanistic evidence includes sex-specific associations between inflammatory markers and depressive symptoms, effects of inflammation on motivation and immuno-metabolic interactions. These findings have informed stratified and enriched trial designs preselecting patients with inflammatory profiles. International initiatives integrate clinical, biomarker, neuroimaging and genetic data to define reproducible signatures. Novel interventions include GLP-1 receptor agonists, more focus on dopaminergic agents and low-dose interleukin-2. Summary Current evidence supports immune-driven depression as a clinically relevant MDD subtype. Indicators such as hsCRP, comorbid metabolic or inflammatory conditions and motivational anhedonia may help clinicians recognize at-risk patients. Most intervention trials remain limited by small, heterogeneous samples and nonspecific outcome measures. Advances in biomarker-guided stratification represent important steps toward precision psychiatry, aiming to develop tailored, mechanism-based treatments for MDD.

• Publication year

  2025

• Venue

  Current Opinion in Psychiatry

• Publication date

  2025-10-23

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/YCO.0000000000001047PMID 41217347PMCID 12672047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotransmitter and metabolic effects of interferon-alpha in association with decreased striatal dopamine in a Non-Human primate model of Cytokine-Induced depression.

  2025cited by this paper
• Anti-inflammatories for depression: challenges and ASPIRations.

  2025cited by this paper
• Relationship between serum oxidative stress and blood brain barrier parameters in patients with major depression.

  2025cited by this paper
• Nutritional Modulation of Impaired Blood-Brain Barrier Integrity and Function in Major Depression

  2025cited by this paper
• Current Position and Future Direction of Inflammation in Neuropsychiatric Disorders: A Review.

  2025cited by this paper
• Add-on probiotics for inflammatory depression - A double-blind randomized placebo-controlled trial.

  2025cited by this paper
• Inflammation and depression: an evolutionary framework for the role of physical activity and exercise

  2025cited by this paper
• Plasma inflammation-related proteins associated with anxiety and depression disorders in IBD patients

  2025cited by this paper
• Advancing an Inflammatory Subtype of Major Depression.

  2025cited by this paper
• Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment

  2025cited by this paper
• Disease Severity Across Psychiatric Disorders Is Linked to Pro-Inflammatory Cytokines

  2025cited by this paper
• Affective disorders and chronic inflammatory conditions: analysis of 1.5 million participants in Our Future Health

  2025cited by this paper
• Immune dysregulation in psychiatric disorders with and without exposure to childhood maltreatment: A transdiagnostic stratified meta-analysis.

  2025cited by this paper
• The role of the kynurenine pathway in cognitive function in brain Disorders: Insights and challenges.

  2025cited by this paper
• Inflammation and metabolic dysfunction underly anhedonia-like behavior in antidepressant resistant male rats.

  2025cited by this paper
• Immune-neuroendocrine crosstalk in mood and psychotic disorders: A meta-analysis and systematic review

  2025cited by this paper
• Integrating plasticity into precision psychiatry

  2025cited by this paper
• Inflammatory markers associated with electroconvulsive therapy response in patients with depression: A meta-analysis.

  2025cited by this paper
• Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression

  2025cited by this paper
• Influence of the COVID-19 pandemic on the prevalence of depression in U.S. adults: evidence from NHANES

  2025cited by this paper
• The immunological perspective of major depressive disorder: unveiling the interactions between central and peripheral immune mechanisms

  2025cited by this paper
• Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.

  2025cited by this paper
• Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial

  2024cited by this paper
• Exposure to parental depression in adolescence and proinflammatory phenotypes 20 years later.

  2024cited by this paper
• Neuroinflammatory imaging markers in white matter: insights into the cerebral consequences of post-acute sequelae of COVID-19 (PASC)

  2024cited by this paper
• A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression

  2024cited by this paper
• Influenza A Virus PB1-F2 Induces Affective Disorder by Interfering Synaptic Plasticity in Hippocampal Dentate Gyrus

  2024cited by this paper
• SARS-CoV-2 Mitochondrial Metabolic and Epigenomic Reprogramming in COVID-19.

  2024cited by this paper
• Inflammation as a mediator between adverse childhood experiences and adult depression: A meta-analytic structural equation model.

  2024cited by this paper
• Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.

  2024cited by this paper
• Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

  2024cited by this paper
• Anhedonia as a potential transdiagnostic phenotype with immune-related changes in recent onset mental health disorders.

  2024cited by this paper
• Blood Immuno-metabolic Biomarker Signatures of Depression and Affective Symptoms in Young Adults

  2024cited by this paper
• COVID-19 is associated with changes in brain function and structure: a multimodal meta-analysis of neuroimaging studies.

  2024cited by this paper
• Examining the genetic links between clusters of immune-mediated diseases and psychiatric disorders

  2024cited by this paper
• Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial

  2024cited by this paper
• Immune-based Machine learning prediction of diagnosis and illness state in schizophrenia and bipolar disorder.

  2024cited by this paper
• Inflammatory Biomarkers and Risk of Psychiatric Disorders.

  2024cited by this paper
• The inflammatory underpinning of depression: An historical perspective.

  2024cited by this paper
• Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo.

  2024cited by this paper
• Long‐term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved

  2024cited by this paper
• A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation

  2024cited by this paper
• Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway

  2024cited by this paper
• Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine

  2024cited by this paper
• Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety Disorders: A secondary analysis of the MOTAR study.

  2024cited by this paper
• Acute and long-term effects of COVID-19 on brain and mental health: A narrative review.

  2024cited by this paper
• The Effect of Exercise on Depression and Gut Microbiota: Possible Mechanisms.

  2024cited by this paper
• Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients.

  2024cited by this paper
• Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation.

  2024cited by this paper
• Immuno-metabolic depression: from concept to implementation

  2024cited by this paper
• Higher Blood-brain barrier permeability in patients with major depressive disorder identified by DCE-MRI imaging.

  2023cited by this paper
• The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder

  2023cited by this paper
• Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials

  2023cited by this paper
• Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers.

  2023cited by this paper
• Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health

  2023cited by this paper
• Infection-associated chronic disability: A transdiagnostic and translational opportunity for neuroscience.

  2023cited by this paper
• Mitochondrial dysfunction: A fatal blow in depression.

  2023cited by this paper
• Inflammation‐stratified augmentation of vortioxetine with celecoxib: Results from a double‐blind, randomized, placebo‐controlled trial in major depressive disorder

  2023cited by this paper
• The HPA Axis as Target for Depression

  2023cited by this paper
• Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

  2023cited by this paper
• Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder

  2023cited by this paper
• Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses

  2023cited by this paper
• Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial

  2022cited by this paper
• Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: a Systematic Review and Meta-Analysis.

  2022cited by this paper
• Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response

  2022cited by this paper
• Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study

  2021cited by this paper
• Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications

  2021cited by this paper
• Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

  2021cited by this paper
• Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder.

  2020cited by this paper
• Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: relevance for symptoms of anxiety and depression.

  2020cited by this paper
• The effects of probiotic supplementation on mental health, biomarkers of inflammation and oxidative stress in patients with psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials.

  2020cited by this paper
• Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium

  2019cited by this paper
• Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein.

  2018cited by this paper
• Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation

  2018cited by this paper
• The role of inflammation in depression: from evolutionary imperative to modern treatment target

  2015cited by this paper
• Depressive-like behavior induced by tumor necrosis factor-α in mice.

  2012cited by this paper
• Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

  2010cited by this paper

• No citing papers are available for this paper.